时事资讯:试验性爱滋病疫苗取得进展

【英文原文】

Experimental HIV Vaccine Gives Some Protection

An experimental vaccine regimen has shown a modest ability to protect people exposed to HIV, the first time an investigational HIV vaccine has been shown to have this effect.

The results from the trial, which involved more than 16,000 adults in Thailand, indicated that the vaccine regimen lowered the rate of contracting HIV by 31% compared with those taking a placebo, according to the U.S. National Institutes of Health, which helped fund the study.

'Additional research is needed to better understand how this vaccine regimen reduced the risk of HIV infection, but certainly this is an encouraging advance for the HIV vaccine field,' said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which is part of the NIH.

It is a rare piece of good news for the field of AIDS vaccine research, which has sponsored more than 100 vaccine trials since 1987 but without any significant success.

The regimen consists of two vaccines. One is a primer dose made by Sanofi Pasteur, the vaccine division of French drug maker Sanofi-Aventis; the other is a booster dose developed by Vaxgen Inc. and now licensed to Global Solutions for Infectious Diseases, in South San Francisco, Calif.